ULTOMIRIS resources

As the committed leader in treatment of atypical-HUS, Alexion draws on more than two decades of research and experience to support you, your patients, their caregivers, and your practice.

For newly diagnosed, treatment-naïve patients to those who are transitioning to a new therapy, we offer several downloadable materials to assist you with caring for your adult and pediatric patients diagnosed with atypical-HUS.

Case studies
Journal articles
For patients

Available materials for download

Discover comprehensive information on treating your patients with atypical-HUS with ULTOMIRIS.


Information about ULTOMIRIS

Whether your patient is newly diagnosed or currently on another treatment, learn about starting your patients with atypical-HUS on the first and only long-acting complement inhibitor for atypical-HUS.


ULTOMIRIS Efficacy and Safety Brochure

Take a closer look at the immediate, complete, and sustained benefits of ULTOMIRIS through the efficacy and safety data demonstrated in clinical trials.


ULTOMIRIS Dosing Guide

Step-by-step instructions for starting treatment-naïve patients on ULTOMIRIS and transitioning patients from eculizumab to ULTOMIRIS.


ULTOMIRIS Nurse Brochure

Support your staff with this guide designed specifically for RNs, NPs, and PAs. The guide provides an overview of ULTOMIRIS for both adult and pediatric patients diagnosed with atypical-HUS, their treatment, recommended dosing, and care.


Perspectives on Transitioning to ULTOMIRIS

Based on interviews with two leading thought leaders in atypical-HUS treatment, this comprehensive perspective provides HCPs with important considerations about transitioning patients from eculizumab to ULTOMIRIS.


ULTOMIRIS Dosing Onesheet

This at-a-glance dosing reference is helpful for understanding the weight-based dosing for ULTOMIRIS.

Case studies

ULTOMIRIS case studies

Find patient profiles and individual case data from patients living with atypical-HUS.


Pediatric Case Study: A Treatment-Naïve Patient

Follow the case of a 4-year-old patient newly diagnosed with atypical-HUS. See this treatment-naïve patient’s response to ULTOMIRIS.


Adult Case Study: Transitioning to ULTOMIRIS

Review the case of a 48-year-old patient with atypical-HUS making the transition from eculizumab to ULTOMIRIS.

Journal articles

Clinical publications

Read clinical trial data and select articles published in peer-reviewed journals.

NOTE: A transfer of value may be associated with these assets.


Atypical-HUS Treatment-Naïve Adult Extension Study
(The 311 Study)

Review the long-term efficacy and safety of the long-acting complement C5 inhibitor for the treatment of adults living with atypical-HUS.

Barbour T, et al. Kidney Int Rep. 2021;24(6):1603-1613.


Atypical-HUS Pediatric Treatment Switch Study
(The 312 Study)

Results from a pediatric patient cohort from the ravulizumab clinical trial who were transitioned from long-term eculizumab to ravulizumab treatment.

Tanaka K, et al. Pediatr Nephrol. 2021;36(4):889-898.


Atypical-HUS Treatment-Naïve Pediatric Extension Study
(The 312 Study)

Long-term results of the effectiveness and safety in pediatric patients with atypical-HUS naïve to complement inhibitor treatment.

Ariceta G, et al. Kidney Int. 2021;100(1):225-237.

For patients

Patient support

Share helpful information and resources to help your patients with atypical-HUS start and stay on ULTOMIRIS.


ULTOMIRIS Atypical-HUS Patient Brochure

Support your patients and caregivers with information about ULTOMIRIS that they can take home and understand. This brochure helps your patients learn more about atypical-HUS as well as what they can expect while starting or transitioning to treatment on ULTOMIRIS.


aHUS Stories: Patrick Starts on ULTOMIRIS

Help parents and caregivers of patients with atypical-HUS see the benefits of ULTOMIRIS through the eyes of others who have been there. This patient-friendly case study follows the family of a 4-year-old boy as they learn to understand the disease and treat their child living with atypical-HUS.


aHUS Stories: Andrew Chooses Transition to ULTOMIRIS

Andrew's experiences transitioning from eculizumab to ULTOMIRIS can help parents and caregivers of patients see the benefits.


Transition FAQ for Atypical-HUS Patients

Help your patients understand the benefits of transitioning with easy-to-understand answers to frequently asked questions.


Patient Resource Kit Request Flyer

We offer a comprehensive Patient Resource Kit to help your patients with atypical-HUS start on ULTOMIRIS. Provide your patients with this flyer so they can easily request this no-cost kit.


Patient Safety Card

As part of the REMS program, please provide your patients with atypical-HUS on ULTOMIRIS with this card that highlights the risk of meningococcal infection.

is here to help

OneSource connects patients, families, and caregivers facing complement-mediated diseases with a dedicated team of support professionals and advocates.

Find support


Alexionʼs customer operations representatives will work with your office distributor or insurance-designated supplier to ensure timely delivery of ULTOMIRIS to your patients.

Let us help you


Show more Show less
Show less


Life-threatening meningococcal infections/sepsis have occurred in patients treated with ULTOMIRIS. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of ULTOMIRIS, unless the risks of delaying ULTOMIRIS therapy outweigh the risk of developing a meningococcal infection. See Warnings and Precautions for additional guidance on the management of the risk of meningococcal infection.
  • Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS REMS.


  • Patients with unresolved Neisseria meningitidis infection.
  • Patients who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying ULTOMIRIS treatment outweigh the risks of developing a meningococcal infection.

Serious Meningococcal Infections

Life-threatening meningococcal infections have occurred in patients treated with ULTOMIRIS. The use of ULTOMIRIS increases a patient’s susceptibility to serious meningococcal infections (septicemia and/or meningitis). Meningococcal disease due to any serogroup may occur.

Vaccinate or revaccinate for meningococcal disease according to the most current ACIP recommendations for patients with complement deficiencies. Immunize patients without history of meningococcal vaccination at least 2 weeks prior to the first dose of ULTOMIRIS. Patients who initiate ULTOMIRIS treatment less than 2 weeks after receiving meningococcal vaccine(s) must receive appropriate prophylactic antibiotics until 2 weeks after vaccination.

The benefits and risks of antibiotic prophylaxis for prevention of meningococcal infections in patients receiving ULTOMIRIS have not been established. Consider discontinuation of ULTOMIRIS in patients who are undergoing treatment for serious meningococcal infection.

Due to the risk of meningococcal infections, ULTOMIRIS is available only through a restricted program under a REMS called ULTOMIRIS REMS.

Under the ULTOMIRIS REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of meningococcal infection/sepsis, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccines.

Additional information on the REMS requirements is available at or 1-888-765-4747.

Other Infections
Patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Children treated with ULTOMIRIS may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP guidelines. If ULTOMIRIS is administered to patients with active systemic infections, monitor closely for worsening infection.

Monitoring Disease Manifestations after ULTOMIRIS Discontinuation
ULTOMIRIS treatment of aHUS should be a minimum duration of 6 months. Due to heterogeneous nature of aHUS events and patient-specific risk factors, treatment duration beyond the initial 6 months should be individualized. There are no specific data on ULTOMIRIS discontinuation. After discontinuing treatment with ULTOMIRIS, patients should be monitored for clinical symptoms and laboratory signs of TMA complications for at least 12 months.

TMA complications post-discontinuation can be identified if any of the following is observed: Clinical symptoms of TMA include changes in mental status, seizures, angina, dyspnea, thrombosis or increasing blood pressure. In addition, at least two of the following laboratory signs observed concurrently and results should be confirmed by a second measurement 28 days apart with no interruption: a decrease in platelet count of 25% or more as compared to either baseline or to peak platelet count during ULTOMIRIS treatment; an increase in serum creatinine of 25% or more as compared to baseline or to nadir during ULTOMIRIS treatment; or, an increase in serum LDH of 25% or more as compared to baseline or to nadir during ULTOMIRIS treatment. If TMA complications occur after discontinuation, consider reinitiation of ULTOMIRIS treatment or appropriate organ-specific supportive measures.

Thromboembolic Event Management
The effect of withdrawal of anticoagulant therapy during treatment with ULTOMIRIS has not been established. Treatment should not alter anticoagulant management.

Infusion-Related Reactions
Intravenous or subcutaneous administration of ULTOMIRIS may result in systemic infusion-related reactions, including anaphylaxis and hypersensitivity reactions. In clinical trials, infusion-related reactions occurred in approximately 1% of patients treated with ULTOMIRIS. These events included lower back pain, drop in blood pressure, elevation in blood pressure, limb discomfort, drug hypersensitivity (allergic reaction), dysgeusia (bad taste), and drowsiness. These reactions did not require discontinuation of ULTOMIRIS. If signs of cardiovascular instability or respiratory compromise occur, interrupt ULTOMIRIS infusion and institute appropriate supportive measures.

Injection Site Reactions-Subcutaneous administration
27% (23/84) of patients treated with subcutaneous administration of ULTOMIRIS experienced injection site reactions which included application site rash, device allergy, infusion site pain, infusion site reaction, injection site bruising, injection site erythema, injection site hematoma, injection site induration, injection site inflammation, injection site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, injection site urticaria, medical device site bruise, medical device site erythema, medical device site hematoma, medical device site induration, medical device site pruritus, medical device site rash, and medical device site reaction.

Allergies to Acrylic Adhesives
The on-body injector of ULTOMIRIS uses acrylic adhesive. For patients with a known allergy to acrylic adhesive, use of this product may result in an allergic reaction. Premedication can be considered, and supportive measures should be instituted if signs of allergy appear.

Most common adverse reactions in patients with aHUS (incidence ≥20%) were upper respiratory tract infection, diarrhea, nausea, vomiting, headache, hypertension and pyrexia. Serious adverse reactions were reported in 42 (57%) patients with aHUS receiving ULTOMIRIS. The most frequent serious adverse reactions reported in more than 2 patients (2.7%) treated with ULTOMIRIS were hypertension, pneumonia and abdominal pain. In clinical studies, clinically relevant adverse reactions in <10% of patients include viral tonsillitis in adults and viral infection in pediatric patients and in 3% of adult patients include infusion-related reactions.

Adverse Reactions for Subcutaneous Administration of ULTOMIRIS

Most common adverse reactions (≥10%) with ULTOMIRIS subcutaneous administration via On Body Injector in adult patients with PNH were local injection site reactions, diarrhea, and headache.


Plasma Exchange, Plasmapheresis, and Intravenous Immunoglobulins

Concomitant use of ULTOMIRIS with plasma exchange (PE), plasmapheresis (PP), or intravenous immunoglobulin (IVIg) treatment can reduce serum ravulizumab concentrations and requires a supplemental dose of ULTOMIRIS.

Neonatal Fc Receptor Blockers

Concomitant use of ULTOMIRIS with neonatal Fc receptor (FcRn) blockers (e.g., efgartigimod) may lower systemic exposures and reduce effectiveness of ULTOMIRIS. Closely monitor for reduced effectiveness of ULTOMIRIS.

ULTOMIRIS is indicated for the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

Limitation of Use:
ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC‑HUS).

Subcutaneous Use in Adult Patients with aHUS
Subcutaneous administration of ULTOMIRIS is not approved for use in pediatric patients.

Please see accompanying full Prescribing Information for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis.

Alexion Connect

Healthcare Professionals:
Answers to your questions are
a phone call away! Connect
with a live representative.

Alexion Connect

Alexion Connect

Healthcare Professionals:
Answers to your questions are
a phone call away! Connect
with a live representative.

Alexion Connect